Kyntra Bio (MEX:KYNB) Research & Development: MXN399.9 Mil (TTM As of Mar. 2026)


MEX:KYNB Kyntra Bio Inc MEX:KYNB
35 GF Score
Price MXN118.50
GF Value MXN94.05
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Kyntra Bio Research & Development?

Kyntra Bio MEX:KYNB 35 Research & Development is MXN399.9 Mil as of Mar. 2026. GuruFocus rates MEX:KYNB with a GF Score™ of 35/100 and a GF Value™ of MXN94.05 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Kyntra Bio's Research & Development for the three months ended in Mar. 2026 was MXN136.4 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was MXN399.9 Mil.

Kyntra Bio  (MEX:KYNB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Kyntra Bio Research & Development Related Terms

Kyntra Bio Research & Development Historical Data

* Premium members only.

The historical data trend for Kyntra Bio's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyntra Bio Research & Development Chart

Kyntra Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7,939.80 5,786.24 4,523.18 1,995.72 423.44

Kyntra Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 187.70 110.43 22.18 130.87 136.44
MEX:KYNB
35GF Score
Kyntra Bio Inc MEX:KYNB
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyntra Bio Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN399.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of MXN399.9 Mil mean?
Kyntra Bio (MEX:KYNB) has a Research & Development of MXN399.9 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Kyntra Bio and its competitors.
Is Kyntra Bio's Research & Development too high?
Kyntra Bio's current Research & Development is MXN399.9 Mil. Overall, Kyntra Bio has a GF Score™ of 35/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's Research & Development compare to SER and SNSE?
Kyntra Bio's Research & Development of MXN399.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Kyntra Bio and its competitors. Kyntra Bio's current Research & Development is MXN399.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (MEX:KYNB) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN94.05, compared to a current price of MXN118.50 — trading 26% above its estimated fair value. The current Research & Development is MXN399.9 Mil. Kyntra Bio's overall GF Score™ is 35/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Kyntra Bio (MEX:KYNB), the current Research & Development is MXN399.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kyntra Bio (MEX:KYNB) Overvalued in 2026?

Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued. The current stock price of MXN118.50 is trading 26% above its estimated GF Value™ of MXN94.05. GuruFocus considers Kyntra Bio to be Modestly Overvalued.

Key valuation signals for MEX:KYNB:

  • Research & Development: MXN399.9 Mil
  • GF Value™: MXN94.05 vs. price of MXN118.50 (26% above fair value)
  • GF Score™: 35/100 with 8 warning signs

No single metric tells the full story. See the MEX:KYNB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kyntra Bio Business Description

Other Exchanges KYNB:USA0IL8:UK1FG0:Germany
Address 350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94133
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
35GF Score

Get the complete analysis for MEX:KYNB

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN118.50
Price
MXN94.05
GF Value